Pregnane X receptor: molecular basis for species differences in CYP3A induction by xenobiotics

E L LeCluyse1

  • 1Division of Drug Delivery and Disposition, School of Pharmacy, University of North Carolina, CB# 7360, Beard Hall, , Chapel Hill, NC 27599-7360, USA.

Insights

Species differences in cytochrome 3A (CYP3A) gene induction by xenobiotics are explained by the pregnane X receptor (PXR). Differences in PXR's ligand-binding domain dictate species-specific responses, impacting drug metabolism and toxicology.

Area of Science:

  • Toxicology
  • Molecular Biology
  • Pharmacology

Background:

  • Species-specific induction of cytochrome 3A (CYP3A) genes by xenobiotics presents a significant challenge in toxicology.
  • The pregnane X receptor (PXR) has emerged as a key regulator of CYP3A gene expression in response to xenobiotics.

Purpose of the Study:

  • To determine the molecular basis for species differences in xenobiotic-mediated CYP3A induction.
  • To investigate the role of the pregnane X receptor (PXR) in mediating these species-specific responses.

Main Methods:

  • Cloning and characterization of orthologous PXR receptors from human, mouse, rat, and rabbit.
  • Assessing the ability of known CYP3A inducers to activate corresponding PXR orthologs.
  • Comparing sequence identity in the DNA-binding and ligand-binding domains of PXR orthologs.

Main Results:

  • Compounds inducing CYP3A in specific species also activated the corresponding PXR orthologs.
  • Selective PXR activators induced CYP3A gene expression in a species-specific manner.
  • High sequence identity (approx. 95%) was observed in the DNA-binding domains, while lower identity (75-80%) was found in the ligand-binding domains of PXR orthologs.

Conclusions:

  • The pregnane X receptor (PXR) is a critical regulator of CYP3A gene expression, and PXR activation predicts CYP3A induction.
  • Sequence variations within the ligand-binding domain of PXR are the primary molecular basis for observed species differences in CYP3A induction.
  • Understanding PXR's role is crucial for predicting drug metabolism and potential toxicity across species.

Related Concept Videos

Transducer Mechanism: Nuclear Receptors01:31

Transducer Mechanism: Nuclear Receptors

Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...